title: Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.
abstract: OBJECTIVE
  To investigate the effects of phosphonoformic acid (PFA) and sevelamer hydrochloride (Renagel) on renal type IIa sodium-dependent phosphate cotransporter (NaPi-2) mRNA expression in hyperphosphatemia rats.
  
  
  METHODS
  Thirty rats were randomly divided into five groups based on the diet for 2 weeks after 5/6 nephrectomy (Nx): Nx + high-phosphate (HP; 1.2% P) diet; Nx + low-phosphate (LP; 0.2% P) diet; HP + PFA (injected with 0.15 g/kg PFA daily); HP + Saline (injected with the same amount of saline daily); and HP + Renagel (2%) group. Another 12 rats were sham operated and divided into Sham + HP and Sham + LP groups. Serum ionized calcium, phosphorus (P), and intact parathyroid hormone (iPTH) were measured on days 2, 7, and 14. Serum 1,25(OH)2D3 was measured on day 14 and NaPi-2 mRNA levels were assayed by RT-PCR.
  
  
  RESULTS
  PFA decreased iPTH level but had no effect on NaPi-2 mRNA expression. Renagel decreased serum P and iPTH levels, but upregulated renal NaPi-2 mRNA expression.
  
  
  CONCLUSIONS
  Both PFA and Renagel are effective drugs to decrease iPTH level and they might be potential candidates for treatment of clinical secondary hyperparathyroidism. Renagel can also decrease serum P and upregulate renal NaPi-2 mRNA expression.
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
authors.forename: Ming
authors.initials: M
authors.lastname: Zeng
authors.forename: Xiaoyun
authors.initials: X
authors.lastname: Wang
authors.forename: Xiaobing
authors.initials: X
authors.lastname: Wang
authors.forename: Xiufen
authors.initials: X
authors.lastname: Zhao
mesh_terms: D000818:Animals; D002614:Chelating Agents / Q000494:pharmacology; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D017245:Foscarnet / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D008297:Male; D010758:Phosphorus / Q000652:urine; D011073:Polyamines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D000069603:Sevelamer; D050613:Sodium-Phosphate Cotransporter Proteins, Type IIa / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D002614:Chelating Agents; D011073:Polyamines; D012333:RNA, Messenger; D018894:Reverse Transcriptase Inhibitors; C493556:Slc34a1 protein, rat; D050613:Sodium-Phosphate Cotransporter Proteins, Type IIa; D010758:Phosphorus; D017245:Foscarnet; D000069603:Sevelamer